No Data
No Data
Jiangsu Recbio Technology Co., Ltd. (HKG:2179) Surges 12%; Individual Investors Who Own 24% Shares Profited Along With Institutions
Express News | Jiangsu Recbio Technology - Hy Loss Attributable RMB247.7 Mln Vs Loss RMB269.1 Mln
Express News | Jiangsu Recbio Technology H1 Capex RMB 78.1 Million
RECBIO-B: UNAUDITED INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024
Ruikang Biologicals (02179.HK) plans to hold a board of directors meeting on August 20 to approve its interim performance.
Ruikang Biology-B (02179.HK) announced on August 8th that the board of directors will hold a meeting on Tuesday, August 20, 2024 to review and approve the unaudited mid-year performance of the company and its subsidiaries as of June 30, 2024 and consider the distribution of interim dividends (if any).
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
No Data
No Data
whqqq : Will they fall after a pandemic?
Spinee OP whqqq : It's hard to say
whqqq Spinee OP : But it can still be held for a short time, right?